

## **BETANAL QUATTRO**

Version 1 / NZ 10200000613 1/11 Revision Date: 02.10.2017 Print Date: 07.12.2017

# SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier	
Trade name	BETANAL QUATTRO
Product code (UVP)	06367933
1.2 Relevant identified uses of	of the substance or mixture and uses advised against
Use	Herbicide
EPA-Nr.	HSR100882
1.3 Details of the supplier of	the safety data sheet
Supplier	Bayer New Zealand Limited 3 Argus Place, Hillcrest Auckland 0627 New Zealand
Telephone	0800 428 246
Telefax	(09) 441 8645
1.4 Emergency telephone no.	
Emergency Number	0800 734 607 (24hr)
Global Incident Response Hotline (24h)	+1 (760) 476-3964 (Company 3E for Bayer AG, Crop Science Division)

## **SECTION 2: HAZARDS IDENTIFICATION**

### 2.1 Classification of the substance or mixture

Classified as hazardous according to the criteria in the Hazardous Substances (Minimum Degrees of Hazard) Regulations 2001

6.1D H332 Harmful if inhaled.
6.9B H373 May cause damage to organs through prolonged or repeated exposure.
9.1B H411 Toxic to aquatic life with long lasting effects.
9.2A H421 Very toxic to the soil environment.
9.3C H433 Harmful to terrestrial vertebrates.

### 2.2 Label elements

Labelling in accordance with Hazardous Substances Identification Regulations 2001



**BETANAL QUATTRO** 

Version 1 / NZ 10200000613 2/11 Revision Date: 02.10.2017 Print Date: 07.12.2017

Hazard label for supply/use required.



Signal word: Warning

### Hazard statements

H332	Harmful if inhaled.
H373	May cause damage to organs through prolonged or repeated exposure.
H411	Toxic to aquatic life with long lasting effects.
H421	Very toxic to the soil environment.
H433	Harmful to terrestrial vertebrates.

#### **Precautionary statements**

P102	Keep out of reach of children.
P260	Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P391	Collect spillage.
P314	Get medical advice/ attention if you feel unwell.
P501	Dispose of contents/container in accordance with local regulation.

#### 2.3 Other hazards

No other hazards known.

### SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.2 Mixtures

#### **Chemical nature**

Suspo-emulsion (SE) 5.5% Phenmedipham (60 g/l), 5.5% Desmedipham (60 g/l), 5.5% Ethofumesate (60 g/l), 18.3% Metamitron (200 g/l)

### Hazardous components

Name	CAS-No.	Conc. [%]
Phenmedipham	13684-63-4	5,50
Desmedipham	13684-56-5	5,50
Ethofumesate	26225-79-6	5,50
Metamitron	41394-05-2	18,30
Ammonium distyrylphenyl ether sulphate	59891-11-1	>= 1,0 - < 3,0
Fatty alcohol ethoxylate	68131-39-5	>= 0,1 - < 1
1,2-Benzisothiazol-3(2H)-one	2634-33-5	>= 0,005 - < 0,05

## **Further information**

Phenmedipham	13684-63-4	M-Factor: 1 (acute)
Desmedipham	13684-56-5	M-Factor: 10 (acute), 10 (chronic)



**BETANAL QUATTRO** 

Version 1 / NZ 10200000613

### **SECTION 4: FIRST AID MEASURES**

4.1 Description of first aid measures		
General advice	Move out of dangerous area. Place and transport victim in stable position (lying sideways). Remove contaminated clothing immediately and dispose of safely.	
Inhalation	Move to fresh air. Keep patient warm and at rest. Call a physician or poison control center immediately.	
Skin contact	Wash off thoroughly with plenty of soap and water, if available with polyethyleneglycol 400, subsequently rinse with water. If symptoms persist, call a physician.	
Eye contact	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation develops and persists.	
Ingestion	Rinse mouth. Do NOT induce vomiting. Call a physician or poison control center immediately.	
4.2 Most important symptoms and effects, both acute and delayed		
Symptoms	Tiredness, Headache, Trembling, Lethargy, Dyspnoea, Ataxia	
4.3 Indication of any immediate medical attention and special treatment needed		
Risks	This product, although being a carbamate, is NOT a cholinesterase inhibitor.	
Treatment	Treat symptomatically. In case of ingestion gastric lavage should be considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium sulphate is always advisable. There is no specific antidote. Forced alkaline diuresis and hemodialysis may be considered.	
Contact the National Poisons and Hazardous Chemicals Information center in Dunedin, PO Box 913, Dunedin. Phone 0800 POISON (0800 764 766).		

### **SECTION 5: FIREFIGHTING MEASURES**

5.1 Extinguishing media	
Suitable	Water spray, Carbon dioxide (CO2), Foam, Sand
Unsuitable	High volume water jet
5.2 Special hazards arising from the substance or mixture	In the event of fire the following may be released:, Hydrogen cyanide (hydrocyanic acid), Carbon monoxide (CO), Sulphur oxides, Nitrogen oxides (NOx)
5.3 Advice for firefighters	
Special protective equipment for firefighters	In the event of fire and/or explosion do not breathe fumes. In the event of fire, wear self-contained breathing apparatus.



**BETANAL QUATTRO** 

Version 1 / NZ 10200000613 **4/11** Revision Date: 02.10.2017 Print Date: 07.12.2017

**Further information** Contain the spread of the fire-fighting media. Do not allow run-off from fire fighting to enter drains or water courses.

## **SECTION 6: ACCIDENTAL RELEASE MEASURES**

6.1 Personal precautions, protective equipment and emergency procedures			
Precautions	Avoid contact with spilled product or contaminated surfaces. Use personal protective equipment.		
6.2 Environmental precautions	Do not allow to get into surface water, drains and ground water.		
6.3 Methods and materials for containment and cleaning up			
Methods for cleaning up	Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Collect and transfer the product into a properly labelled and tightly closed container.		
Additional advice	Check also for any local site procedures.		
6.4 Reference to other sections	Information regarding safe handling, see section 7. Information regarding personal protective equipment, see section 8. Information regarding waste disposal, see section 13.		

### **SECTION 7: HANDLING AND STORAGE**

### 7.1 Precautions for safe handling

Advice on safe handling	Use only in area provided with appropriate exhaust ventilation.
Advice on protection against fire and explosion	No special precautions required.
Hygiene measures	Avoid contact with skin, eyes and clothing. Keep working clothes separately. Wash hands immediately after work, if necessary take a shower. Remove soiled clothing immediately and clean thoroughly before using again.
7.2 Conditions for safe storage	ge, including any incompatibilities
Requirements for storage areas and containers	Store in original container. Store in a place accessible by authorized persons only. Keep containers tightly closed in a dry, cool and well-ventilated place. Protect from frost. Keep away from direct sunlight.
Advice on common storage	Keep away from food, drink and animal feedingstuffs.
Suitable materials	HDPE (high density polyethylene)
7.3 Specific end use(s)	Refer to the label and/or leaflet.



## **BETANAL QUATTRO**

Version 1 / NZ 10200000613 5/11 Revision Date: 02.10.2017 Print Date: 07.12.2017

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis
Phenmedipham	13684-63-4	1,5 mg/m3 (TWA)		OES BCS*
Desmedipham	13684-56-5	1,2 mg/m3 (TWA)		OES BCS*
Ethofumesate	26225-79-6	10 mg/m3 (TWA)		OES BCS*

\*OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

### 8.2 Exposure controls

#### Personal protective equipment

In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the following recommendations would apply.

tollowing recommendations would			
Respiratory protection	Respiratory protection is not required under anticipated circumstances of exposure.		
	Respiratory protection should only be used to control residual risk		
	short duration activities, when all reasonably practicable steps have		
	been taken to reduce exposure at source e.g. containment and/or		
		ays follow respirator manufacturer's	
	instructions regarding wear	ng and maintenance.	
Hand protection		ions regarding permeability and	
		e provided by the supplier of the gloves.	
		the specific local conditions under which	
	the product is used, such as contact time.	s the danger of cuts, abrasion, and the	
		nated. Dispose of when contaminated	
		when contamination on the outside cannot	
		requently and always before eating,	
	drinking, smoking or using t		
	Material	Nitrile rubber	
	Rate of permeability	> 480 min	
	Glove thickness	> 0,4 mm	
	Protective index	Class 6	
	Directive	Protective gloves complying with EN 374.	
Eye protection	Wear goggles (conforming	to EN166, Field of Use = 5 or equivalent).	
Skin and body protection	Wear standard coveralls an		
	If there is a risk of significant exposure, consider a higher protective		
	type suit.		
	Wear two layers of clothing wherever possible. Polyester/cotton cotton overalls should be worn under chemical protection suit ar		
	should be professionally laundered frequently. If chemical protection suit is splashed, sprayed or significantly		
	contaminated, decontaminate as far as possible, then carefully		
	remove and dispose of as a		
General protective measures		not enclosed, and if contact may occur:	
	Complete suit protecting ag	ainst chemicals	



**BETANAL QUATTRO** 

Version 1 / NZ 10200000613

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties		
Form	suspension	
Colour	white to light beige	
Odour	aromatic	
рН	4,0 - 7,0 at 10 % (23 °C) (deionized water)	
Flash point	>100 °C No flash point - Determination conducted up to the boiling point.	
Density	ca. 1,09 g/cm³ at 20 °C	
Water solubility	dispersible	
Partition coefficient: n- octanol/water	Phenmedipham: log Pow: 3,59	
	Desmedipham: log Pow: 3,39 Ethofumesate: log Pow: 2,7 at 25 °C Metamitron: log Pow: 0,86	
Viscosity, dynamic	150 - 350 mPa.s at 20 °C Velocity gradient 20 /s	
	50 - 160 mPa.s at 20 °C Velocity gradient 100 /s	
Surface tension	ca. 39 mN/m Determined as a 0,1% solution in distilled water (1 g/l).	
9.2 Other information	Further safety related physical-chemical data are not known.	

## SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity	
Thermal decomposition	Stable under normal conditions.
10.2 Chemical stability	Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions	No hazardous reactions when stored and handled according to prescribed instructions.
10.4 Conditions to avoid	Extremes of temperature and direct sunlight.
10.5 Incompatible materials	Store only in the original container.
10.6 Hazardous decomposition products	No decomposition products expected under normal conditions of use.

## SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

**BETANAL QUATTRO** 





7/11 Revision Date: 02.10.2017 Print Date: 07.12.2017

Acute oral toxicity	LD50 (Rat) > 2.000 mg/kg
Acute inhalation toxicity	
	During intended and foreseen applications, no respirable aerosol is formed.
Acute dermal toxicity	LD50 (Rat) > 4.000 mg/kg
Skin irritation	No skin irritation (Rabbit)
Eye irritation	Slight irritant effect - does not require labelling. (Rabbit)
Sensitisation	Non-sensitizing. (Guinea pig) OECD Test Guideline 406, Buehler test Sensitising (Mouse) OECD Test Guideline 429, local lymph node assay (LLNA)

#### Assessment STOT Specific target organ toxicity - single exposure

Phenmedipham: Based on available data, the classification criteria are not met.

Desmedipham: Based on available data, the classification criteria are not met.

Ethofumesate: Based on available data, the classification criteria are not met.

Metamitron: Based on available data, the classification criteria are not met.

### Assessment STOT Specific target organ toxicity – repeated exposure

Phenmedipham caused haemolytic anaemia, methaemoglobinaemia in animal studies. The observed effects do not appear to be relevant for humans.

Desmedipham caused methaemoglobinaemia, haemolytic anaemia in animal studies. The observed effects do not appear to be relevant for humans.

Ethofumesate did not cause specific target organ toxicity in experimental animal studies.

Metamitron did not cause specific target organ toxicity in experimental animal studies.

### Assessment mutagenicity

Phenmedipham was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Desmedipham was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Ethofumesate was not mutagenic or genotoxic in a battery of in vitro and in vivo tests. Metamitron was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

#### Assessment carcinogenicity

Phenmedipham was not carcinogenic in lifetime feeding studies in rats and mice. Desmedipham was not carcinogenic in lifetime feeding studies in rats and mice. Ethofumesate was not carcinogenic in lifetime feeding studies in rats and mice. Metamitron was not carcinogenic in lifetime feeding studies in rats and mice.

#### Assessment toxicity to reproduction

Phenmedipham caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Phenmedipham is related to parental toxicity.

Desmedipham caused a reduced litter size and a reduced pup weight. The reproduction toxicity seen with Desmedipham is related to parental toxicity.

Ethofumesate did not cause reproductive toxicity in a two-generation study in rats.

Metamitron did not cause reproductive toxicity in a two-generation study in rats.

#### Assessment developmental toxicity



## **BETANAL QUATTRO**

Version 1 / NZ 10200000613

**8/11** Revision Date: 02.10.2017 Print Date: 07.12.2017

Phenmedipham caused developmental toxicity only at dose levels toxic to the dams. Phenmedipham caused a delayed ossification of foetuses. The developmental effects seen with Phenmedipham are related to maternal toxicity.

Desmedipham caused developmental toxicity only at dose levels toxic to the dams. Desmedipham caused a delayed ossification of foetuses, an increased incidence of variations. The developmental effects seen with Desmedipham are related to maternal toxicity.

Ethofumesate did not cause developmental toxicity in rats and rabbits.

Metamitron did not cause developmental toxicity in rats and rabbits.

#### Aspiration hazard

Based on available data, the classification criteria are not met.

### **SECTION 12: ECOLOGICAL INFORMATION**

12.1 Toxicity	
Toxicity to fish	LC50 (Oncorhynchus mykiss (rainbow trout)) 35 mg/l static test; Exposure time: 96 h
Toxicity to aquatic invertebrates	EC50 (Daphnia magna (Water flea)) 8,2 mg/l static test; Exposure time: 48 h
Chronic toxicity to aquatic invertebrates	NOEC (Daphnia (water flea)): 0,01 mg/l Exposure time: 21 d The value mentioned relates to the active ingredient desmedipham.
Toxicity to aquatic plants	IC50 (Desmodesmus subspicatus (green algae)) 8,6 mg/l static test; Exposure time: 72 h
12.2 Persistence and degradability	
Biodegradability	Phenmedipham: Not rapidly biodegradable Desmedipham: Not rapidly biodegradable Ethofumesate: Not rapidly biodegradable Metamitron: Not rapidly biodegradable
Кос	Phenmedipham: Koc: 888 Desmedipham: Koc: > 5000 Ethofumesate: Koc: 147 Metamitron: Koc: 86,4
12.3 Bioaccumulative potential	
Bioaccumulation	Phenmedipham: Bioconcentration factor (BCF) 165 Does not bioaccumulate. Desmedipham: Bioconcentration factor (BCF) 157 Does not bioaccumulate. Ethofumesate: Bioconcentration factor (BCF) 144 Does not bioaccumulate. Metamitron:

**BETANAL QUATTRO** 



BAYER

**9/11** Revision Date: 02.10.2017 Print Date: 07.12.2017

	Does not bioaccumulate.
12.4 Mobility in soil	
Mobility in soil	Phenmedipham: Slightly mobile in soils Desmedipham: Immobile in soil Ethofumesate: Moderately mobile in soils Metamitron: Moderately mobile in soils
12.5 Results of PBT and vPvE	3 assessment
PBT and vPvB assessment	Phenmedipham: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Desmedipham: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Ethofumesate: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Ethofumesate: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Metamitron: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
12.6 Other adverse effects	
Additional ecological information	No other effects to be mentioned.

### **SECTION 13: DISPOSAL CONSIDERATIONS**

#### 13.1 Waste treatment methods

Product	Dispose of this product only by using according to the label, or at an approved landfill or other approved facility.
Contaminated packaging	Triple rinse containers. Recycle if possible. If allowed under local authority, burn if circumstances, especially wind direction permit, otherwise crush and bury in an approved local authority facility. Do not use container for any other purpose.

### **SECTION 14: TRANSPORT INFORMATION**

This transportation information is not intended to convey all specific regulatory information relating to this product. It does not address regulatory variations due to package size or special transportation requirements.

ADR/RID/ADN 14.1 UN number 14.2 Proper shipping name 14.3 Transport hazard class(es)	<b>3082</b> ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE, METAMITRON SOLUTION) 9
14.4 Packing group	III
14.5 Environm. Hazardous Mark	YES

## **BETANAL QUATTRO**

Version 1 / NZ 10200000613



**10/11** Revision Date: 02.10.2017 Print Date: 07.12.2017

Hazchem Code	3Z
<b>IMDG</b> 14.1 UN number 14.2 Proper shipping name	<b>3082</b> ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE, METAMITRON SOLUTION)
14.3 Transport hazard class(es) 14.4 Packing group 14.5 Marine pollutant	9 III YES
ΙΑΤΑ	
14.1 UN number 14.2 Proper shipping name	<b>3082</b> ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
14.3 Transport hazard class(es) 14.4 Packing group 14.5 Environm. Hazardous Mark	(PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE, METAMITRON SOLUTION ) 9 III YES

### 14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

## 14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code

No transport in bulk according to the IBC Code.

### **SECTION 15: REGULATORY INFORMATION**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **Further information**

HSNO approval-Nr.	HSR100882
HSNO Controls	See www.epa.govt.nz
ACVM Reg.	P8851
ACVM Condition	See www.foodsafety.govt.nz

### **SECTION 16: OTHER INFORMATION**

#### Abbreviations and acronyms

ADN	European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways
ADR	European Agreement concerning the International Carriage of Dangerous Goods by
	Road
ATE	Acute toxicity estimate
CAS-Nr.	Chemical Abstracts Service number
Conc.	Concentration
ECx	Effective concentration to x %



## **BETANAL QUATTRO**

Version 1 / NZ 10200000613 **11/11** Revision Date: 02.10.2017 Print Date: 07.12.2017

EINECS ELINCS EN EU	European inventory of existing commercial substances European list of notified chemical substances European Standard European Union
IATA	International Air Transport Association
IBC	International Code for the Construction and Equipment of Ships Carrying Dangerous Chemicals in Bulk (IBC Code)
ICx	Inhibition concentration to x %
IMDG	International Maritime Dangerous Goods
LCx	Lethal concentration to x %
LDx	Lethal dose to x %
LOEC/LOEL	Lowest observed effect concentration/level
MARPOL	MARPOL: International Convention for the prevention of marine pollution from ships
N.O.S.	Not otherwise specified
NOEC/NOEL	No observed effect concentration/level
OECD	Organization for Economic Co-operation and Development
RID	Regulations concerning the International Carriage of Dangerous Goods by Rail
TWA	Time weighted average
UN	United Nations
WHO	World health organisation

The data given here is based on current knowledge and experience. The purpose of this Safety Data Sheet is to describe products in terms of their safety requirements. The above details do not imply any guarantee concerning composition, properties or performance of the product.

Reason for Revision: Section 2: Hazards Identification. Section 3: Composition / Information on Ingredients. Section 8: Exposure Controls / Personal Protection. Section 11: Toxicological information on STOT (Specific Target Organ Toxicity) and CMR (Carcinogenic, Mutagenic and toxic to Reproduction).

Changes since the last version are highlighted in the margin. This version replaces all previous versions.